CD33 and in situ carcinoma: In Myeloid cell panel, CD45 on Immature Myeloid-Derived Suppressor Cells (OR=1.65, 95%CI:1.016-2.679, P=0.043) was linked in a higher incidence risk, while CD33+ HLA DR+ CD14dim, Granulocytic Myeloid-Derived Suppressor Cells, CD33 on CD14+ monocyte, CD33 on CD33dim HLA DR+ CD11b+, CD33 on CD33dim HLA DR+ CD11b-, and CD33 on basophil were protective factors for carcinoma in situ of endometrium.